ACLX (Arcellx, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ACLX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-28 | Ali Behbahani | Director | U | — | — |
| 2026-04-28 | Kavita Patel | Director | D | — | — |
| 2026-04-28 | David Charles Lubner | Director | U | — | — |
| 2026-04-28 | Jill Carroll | Director | U | — | — |
| 2026-04-28 | Olivia C Ware | Director | D | — | — |
| 2026-04-28 | Andrew H Galligan | Director | U | — | — |
| 2026-04-28 | Kristin Myers | Director | D | — | — |
| 2026-04-28 | Michelle Gilson | CHIEF FINANCIAL OFFICER | U | — | — |
| 2026-04-28 | Christopher Heery | CHIEF MEDICAL OFFICER | U | — | — |
| 2026-04-28 | Rami Elghandour | SEE REMARKS | U | — | — |
| 2026-04-17 | Michelle Gilson | CHIEF FINANCIAL OFFICER | M | — | — |
| 2026-03-19 | Michelle Gilson | CHIEF FINANCIAL OFFICER | G | — | — |
| 2026-03-04 | Rami Elghandour | SEE REMARKS | G | — | — |
| 2026-02-27 | Rami Elghandour | SEE REMARKS | MIXED | — | — |
| 2026-02-25 | Michelle Gilson | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-02-19 | Michelle Gilson | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-02-18 | Michelle Gilson | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2026-02-13 | Rami Elghandour | SEE REMARKS | G | — | — |
| 2026-02-13 | Rami Elghandour | SEE REMARKS | G | — | — |
| 2026-01-20 | David Charles Lubner | Director | MIXED | — | — |
| 2026-01-14 | Christopher Heery | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-01-13 | Christopher Heery | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-01-12 | Christopher Heery | CHIEF MEDICAL OFFICER | MIXED | — | — |
| 2026-01-06 | Michelle Gilson | CHIEF FINANCIAL OFFICER | M | — | — |
| 2026-01-06 | Rami Elghandour | SEE REMARKS | M | — | — |
| 2026-01-06 | Christopher Heery | CHIEF MEDICAL OFFICER | M | — | — |
| 2025-11-17 | Christopher Heery | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2025-10-15 | Michelle Gilson | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2025-10-06 | Michelle Gilson | CHIEF FINANCIAL OFFICER | Sell | — | — |
| 2025-09-30 | Christopher Heery | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2025-09-29 | Christopher Heery | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2025-09-26 | Christopher Heery | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2025-09-19 | Christopher Heery | CHIEF MEDICAL OFFICER | Sell | — | — |
| 2025-08-29 | Rami Elghandour | SEE REMARKS | F | — | — |
| 2025-08-14 | Ali Behbahani | Director | J | — | — |
| 2025-06-11 | Kavita Patel | Director | MIXED | — | — |
| 2025-05-30 | David Charles Lubner | Director | A | — | — |
| 2025-05-30 | Kristin Myers | Director | A | — | — |
| 2025-05-30 | Kavita Patel | Director | A | — | — |
| 2025-05-30 | Jill Carroll | Director | A | — | — |
| 2025-05-30 | Andrew H Galligan | Director | A | — | — |
| 2025-05-30 | Olivia C Ware | Director | A | — | — |
| 2025-05-30 | Ali Behbahani | Director | A | — | — |
| 2025-05-28 | Michelle Gilson | CHIEF FINANCIAL OFFICER | MIXED | — | — |
| 2025-05-20 | Kavita Patel | Director | MIXED | — | — |
| 2025-04-29 | Kavita Patel | Director | MIXED | — | — |
| 2025-04-08 | Kavita Patel | Director | MIXED | — | — |
| 2025-03-20 | Andrew H Galligan | Director | A | — | — |
| 2025-03-20 | Kristin Myers | Director | A | — | — |
| 2025-03-18 | Kavita Patel | Director | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 6,746,494 | — |
| — | 10%+ Owner | 4,850,214 | — |
| — | 10%+ Owner | 4,745,262 | — |
| — | 10%+ Owner | 4,745,262 | — |
| — | 10%+ Owner | 3,183,545 | — |
| — | 10%+ Owner | 2,828,394 | — |
| — | 10%+ Owner | 2,216,960 | — |
| — | Director | 2,095,114 | — |
| — | 10%+ Owner | 30,283 | — |
| — | Director | 9,402 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ACLX quote page; the site-wide leaderboard is on the insider transactions hub.